Baylor College of Medicine
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Baylor College of Medicine sits in the top decile of US sponsors by registered trial count (#56 of 15,742 sponsors by registered trial count).
Baylor College of Medicine: 616 sponsored US clinical trials, 93 recruiting.
Baylor College of Medicine sponsors 616 registered US clinical trials on ClinicalTrials.gov, 93 of them currently recruiting, and 376 completed. 59 of these trials are in Phase 3-4 (later-stage) and 232 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Hodgkin Lymphoma, with 7 trials.
Top-decile sponsor footprint
Baylor College of Medicine ranks in the top decile of sponsors by registered trial count (#56 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
376 of 452 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
616 total, page 2 of 13
Arginine Metabolism in Youth With Type 2 Diabetes
NCT05477134
CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD
NCT05609916
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
NCT04664179
Systematic Light Exposure in Pediatric Brain Tumor Survivors
NCT05340881
Microphthalmia, Anophthalmia, and Coloboma Genetic Epidemiology in Children
NCT06293560
IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department
NCT05304442
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
NCT05132504
Genetic Inclusion by Virtual Evaluation
NCT05318222
Improving Comprehensive Care of Cancer Patients
NCT05323409
Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing
NCT05418894
Hepatic Histopathology in Urea Cycle Disorders
NCT04908319
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
NCT04740580
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
NCT05489042
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
NCT04995003
Liver Disease in Urea Cycle Disorders
NCT04612764
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
NCT03690011
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
NCT05283811
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
NCT04013802
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
NCT04626024
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
NCT03740256
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
NCT04288726
Genetic Disorders of Obesity Program Database
NCT05747976
The Effect of Fluids on Aortic VTI During C-section
NCT04330742
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
NCT04099797
DBS for Depression
NCT03437928
High Dose Albumin in Refractory Ascites
NCT05867602
Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?
NCT03823742
Natural History Study and Establishment of a Biorepository-TANGO2-related Disorder
NCT05374616
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
NCT03384563
GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma
NCT03294954
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
NCT03081910
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
NCT02917083
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
NCT02670707
BBD Longitudinal Study of Osteogenesis Imperfecta
NCT02432625
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
NCT02291848
Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial
NCT02610179
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
NCT01940757
Standardized Prenatal Clinical Care for LUTO
NCT02315521
CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft
NCT02089607
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
NCT01853631
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
NCT01555892
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
NCT01189786
Study of Selected X-Linked Disorders: Aicardi Syndrome
NCT00697411
Trigeminal Nerve Stimulation of the Treatment of Epilepsy
NCT07220161
Feasibility of the Paso Program for Patients With Metabolic Dysfunction Associated Steatotic Liver Disease
NCT06854185
upREACH Perinatal Home Visitation Program
NCT06133829
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
NCT05236764
Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement
NCT06577220
Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder
NCT05967468
Neurodevelopmental Outcomes in Children: Strengthening the Caregiver-Child Story
NCT05809115
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 173 |
| Phase 2 | 59 |
| Phase 3 | 13 |
| Phase 4 | 46 |
Therapeutic Areas
What is open in the Baylor College of Medicine pipeline
93 recruiting of 616 indexed (15% open); 376 completed (61%).
Phase mix: 59 late (III/IV) vs 232 early (I/II) (early-phase heavy).
Top condition: Non-Hodgkin Lymphoma (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Baylor College of Medicine: open-pipeline peers nationwide
Peers matched on 616 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Baylor College of Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 616 trials (± recruiting share)
- University of Southern California · 617 trials · 16% recruiting
- US Department of Veterans Affairs · 632 trials · 0% recruiting
- University of Rochester · 636 trials · 15% recruiting
- Janssen Research & Development · 593 trials · 11% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Stanford University · 15% recruiting · 1,744 trials
- Baylor University · 15% recruiting · 33 trials
- Cornell University · 15% recruiting · 66 trials
- 59th Medical Wing · 15% recruiting · 20 trials
Related
What to do with this Baylor College of Medicine page
616 registered trials is a research-attention snapshot, not an endorsement of Baylor College of Medicine or any single study.
- 93 of Baylor College of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Hodgkin Lymphoma is the condition Baylor College of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Hodgkin Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Baylor College of Medicine pipeline card: 616 registered trials from official public datasets.Report a data error.